title: Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays.
abstract: The replication fitness of HIV-1 drug-resistant mutants has been measured using either multiple-cycle or single-cycle assays (MCAs or SCAs); these assays have not been systematically compared. We developed an MCA and an SCA that utilized either intact or env-deleted recombinant viral vectors, respectively, in which virus-infected cells were detected by flow cytometry of a reporter gene product. Fitness was measured using each assay for 11 protease mutants, 9 reverse transcriptase mutants, and two mutants with mutations in gag p6, which is important for the release of virus particles from the cell membrane. In the SCA, fitness (replication capacity [RC]) was defined as the proportion of cells infected by the mutant compared to the wild type 40 h after infection. MCA fitness (1+s) was determined by comparing the changes in the relative proportions of cells infected by the mutant and the wild type between 3 and 5 days after infection. Five protease mutants showed statistically different fitness values by the MCA versus the SCA: the D30N, G48V, I50V, I54L, and I54M mutants. When all the mutants were ranked in order from most to least fit for both assays, 4 protease mutants moved more than 5 positions in rank: the D30N, I54L, I54M, and V82A mutants. There were no significant differences in fitness for the gag p6 or reverse transcriptase mutants. We propose that discordant results in the MCA and SCA are due to alterations in late events in the virus life cycle that are not captured in an SCA, such as burst size, cell-to-cell transmission, or infected-cell life span.
authors.affiliation: Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA. carrie_dykes@urmc.rochester.edu
authors.forename: Carrie
authors.initials: C
authors.lastname: Dykes
authors.forename: Hulin
authors.initials: H
authors.lastname: Wu
authors.forename: Matthew
authors.initials: M
authors.lastname: Sims
authors.forename: Jeanne
authors.initials: J
authors.lastname: Holden-Wiltse
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Demeter
mesh_terms: D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000821:virology*; D016333:HIV Protease / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D014773:Virology / Q000379:methods; D014774:Virulence; D014779:Virus Replication
chemical_list: D017320:HIV Protease Inhibitors; D016333:HIV Protease; C514803:p16 protease, Human immunodeficiency virus 1
references.citation: Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3195-9
references.pmid: 2014240
references.citation: J Virol. 2005 Jul;79(14):8979-90
references.pmid: 15994792
references.citation: Virology. 2004 Sep 1;326(2):262-79
references.pmid: 15302212
references.citation: J Virol. 2010 Aug;84(15):7581-91
references.pmid: 20504921
references.citation: J Virol. 1995 Jun;69(6):3712-20
references.pmid: 7745720
references.citation: Virology. 2006 Sep 15;353(1):184-92
references.pmid: 16797050
references.citation: J Virol. 2006 Mar;80(5):2380-9
references.pmid: 16474144
references.citation: J Virol. 2002 Nov;76(21):11104-12
references.pmid: 12368352
references.citation: J Virol. 1998 May;72(5):3773-8
references.pmid: 9557659
references.citation: J Virol. 2001 Oct;75(20):9644-53
references.pmid: 11559796
references.citation: J Virol. 2000 Oct;74(20):9339-46
references.pmid: 11000201
references.citation: J Virol. 2007 Mar;81(6):3037-41
references.pmid: 17192300
references.citation: J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):411-7
references.pmid: 17554216
references.citation: J Virol. 1996 Apr;70(4):2581-5
references.pmid: 8642689
references.citation: Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9564-8
references.pmid: 7937806
references.citation: J Virol. 2004 Feb;78(4):1718-29
references.pmid: 14747537
references.citation: Clin Microbiol Rev. 2007 Oct;20(4):550-78
references.pmid: 17934074
references.citation: J Virol. 2009 Jan;83(1):140-9
references.pmid: 18971283
references.citation: J Clin Microbiol. 2006 Jun;44(6):1930-43
references.pmid: 16757582
references.citation: Trends Microbiol. 2003 Feb;11(2):56-9
references.pmid: 12598123
references.citation: Eur J Biochem. 1999 Jul;263(1):238-45
references.pmid: 10429209
references.citation: J Virol. 2003 Sep;77(18):10172-5
references.pmid: 12941931
references.citation: J Virol. 2000 Sep;74(18):8390-401
references.pmid: 10954539
references.citation: Antimicrob Agents Chemother. 2000 Apr;44(4):920-8
references.pmid: 10722492
references.citation: J Virol. 2000 Sep;74(18):8524-31
references.pmid: 10954553
references.citation: J Virol. 1999 Jul;73(7):5803-13
references.pmid: 10364332
references.citation: Biochemistry. 2003 Dec 30;42(51):15029-35
references.pmid: 14690411
references.citation: J Biol Chem. 2004 Jan 2;279(1):509-16
references.pmid: 14551187
references.citation: J Virol. 1997 Aug;71(8):5871-7
references.pmid: 9223476
references.citation: AIDS. 2002 May 3;16(7):1009-17
references.pmid: 11953467
references.citation: Gene. 1985;40(1):1-8
references.pmid: 3912262
references.citation: J Virol. 1999 May;73(5):3744-52
references.pmid: 10196268
references.citation: Science. 1995 Jan 27;267(5197):483-9
references.pmid: 7824947
references.citation: J Virol. 2004 May;78(9):4628-37
references.pmid: 15078945
references.citation: J Virol. 2007 May;81(9):4540-50
references.pmid: 17287264
references.citation: J Virol. 2003 Nov;77(22):12105-12
references.pmid: 14581547
references.citation: Virology. 2006 May 10;348(2):462-74
references.pmid: 16504235
references.citation: Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15266-71
references.pmid: 8986799
references.citation: Antivir Chem Chemother. 2002 Jan;13(1):27-37
references.pmid: 12180647
references.citation: Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11395-9
references.pmid: 8876146
references.citation: Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1648-53
references.pmid: 8643685
references.citation: Rev Med Virol. 1997 Jul;7(2):87-96
references.pmid: 10398474
references.citation: J Virol. 2008 Jan;82(1):495-502
references.pmid: 17942528
references.citation: Science. 1989 Mar 31;243(4899):1731-4
references.pmid: 2467383
references.citation: J Virol. 1991 Jan;65(1):162-9
references.pmid: 1845882
references.citation: J Virol. 2004 Jan;78(2):603-11
references.pmid: 14694092
references.citation: J Infect Dis. 2004 Jul 15;190(2):251-6
references.pmid: 15216458
references.citation: Virology. 2001 Jul 5;285(2):193-203
references.pmid: 11437654
references.citation: J Acquir Immune Defic Syndr. 2001 May 1;27(1):7-13
references.pmid: 11404514
references.citation: Science. 1985 Aug 9;229(4713):563-6
references.pmid: 2992081
references.citation: Biochemistry. 2002 Jul 9;41(27):8613-9
references.pmid: 12093278